The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients

被引:151
作者
Joynt, GM [1 ]
Lipman, J
Gomersall, CD
Young, RJ
Wong, ELY
Gin, T
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China
[2] Univ Queensland, Div Anaesthesiol & Intens Care, St Lucia, Qld 4067, Australia
[3] Royal Brisbane Hosp, Intens Care Facil, Brisbane, Qld, Australia
关键词
D O I
10.1093/jac/47.4.421
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of this study was to determine the pharmacokinetic profile of the normal recommended dose of ceftriaxone in critically ill patients and to establish whether the current daily dosing recommendation maintains plasma concentrations adequate for antibacterial efficacy. Ceftriaxone at a recommended dose of 2 g iv was administered od to 12 critically ill patients with severe sepsis and normal serum creatinine concentrations. Blood samples were taken at predetermined intervals over the first 24 h and on day 3 for measurement of ceftriaxone concentrations. There was wide variability in drug disposition, explained by the presence of variable renal function and identified by the measurement of creatinine clearance. In nine patients with normal renal function, there was a high level of creatinine clearance(mean +/- S.D., 41 +/- 12 mL/min) and volume of distribution (20 +/- 3.3 L), which resulted in an elimination half-life of 6.4 +/- 1.1 h. In comparison with normal subjects, ceftriaxone clearance was increased 100%, volume of distribution increased 90% and the elimination half-life was similar. Three patients had substantially suboptimal plasma ceftriaxone concentrations. We confirm previous findings that ceftriaxone clearance in critically ill patients correlates with renal clearance by glomerular filtration. The elimination half-life is prolonged (21.4 +/- 9.8 h) in critically ill patients with renal failure when compared with previously published data in non-critically ill patients with renal failure. We conclude that in critically ill patients with normal renal function, inadequate plasma concentrations may result following od bolus dosing of ceftriaxone. Drug accumulation may occur in critically ill patients with renal failure.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 41 条
[2]   CEFTRIAXONE - A REAPPRAISAL OF ITS ANTIBACTERIAL ACTIVITY AND PHARMACOKINETIC PROPERTIES, AND AN UPDATE ON ITS THERAPEUTIC USE WITH PARTICULAR REFERENCE TO ONCE-DAILY ADMINISTRATION [J].
BROGDEN, RN ;
WARD, A .
DRUGS, 1988, 35 (06) :604-645
[3]   ACCUMULATION OF MIDAZOLAM AFTER REPEATED DOSAGE IN PATIENTS RECEIVING MECHANICAL VENTILATION IN AN INTENSIVE-CARE UNIT [J].
BYATT, CM ;
LEWIS, LD ;
DAWLING, S ;
COCHRANE, GM .
BRITISH MEDICAL JOURNAL, 1984, 289 (6448) :799-800
[4]   Pharmacokinetics of aztreonam in critically ill surgical patients [J].
Cornwell, EE ;
Belzberg, H ;
Berne, TV ;
Gill, MA ;
Theodorou, D ;
Kern, JW ;
Yu, W ;
Asensio, J ;
Demetriades, D .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (05) :537-540
[5]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[6]   CONDITIONS FOR THE EMERGENCE OF RESISTANCE TO CEFPIROME AND CEFTAZIDIME IN EXPERIMENTAL ENDOCARDITIS DUE TO PSEUDOMONAS-AERUGINOSA [J].
FANTIN, B ;
FARINOTTI, R ;
THABAUT, A ;
CARBON, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (03) :563-569
[7]  
GOLDSTEIN A, 1949, PHARMACOL REV, V1, P102
[8]   Changes in vancomycin pharmacokinetics in critically ill infants [J].
Gous, AGS ;
Dance, MD ;
Lipman, J ;
Luyt, DK ;
Mathivha, R ;
Scribante, J .
ANAESTHESIA AND INTENSIVE CARE, 1995, 23 (06) :678-682
[9]   ION-PAIR HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR CEFTRIAXONE [J].
GRANICH, GG ;
KROGSTAD, DJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (03) :385-388
[10]   Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries [J].
Hanberger, H ;
Garcia-Rodriguez, JA ;
Gobernado, M ;
Goossens, H ;
Nilsson, LE ;
Struelens, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (01) :67-71